KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
12.09
+0.34 (2.89%)
Apr 17, 2025, 4:00 PM EDT - Market closed
KalVista Pharmaceuticals Employees
KalVista Pharmaceuticals had 150 employees as of April 30, 2024. The number of employees increased by 32 or 27.12% compared to the previous year.
Employees
150
Change (1Y)
32
Growth (1Y)
27.12%
Revenue / Employee
n/a
Profits / Employee
-$1,172,447
Market Cap
596.59M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
KALV News
- 8 days ago - KalVista: Poised For Rare Disease Transformation - Seeking Alpha
- 12 days ago - KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan - Business Wire
- 18 days ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 20 days ago - KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference - Business Wire
- 26 days ago - KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial - Business Wire
- 5 weeks ago - KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update - Business Wire
- 5 weeks ago - KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema - Business Wire
- 6 weeks ago - KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting - Business Wire